Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (933)	10/16/1998 11:12:00 AM
From: aknahow	Read Replies (1) \| Respond to of 1722

Anthony Wong, tried to send this URL by private message but for reasons not understood, I couldn't. pharminfo.com It does not belong on this thread but if you have not seen it it can be of use. BTW thanks for your many dedicated post. I find this board of real value due in large part to you.

To: Anthony Wong who wrote (933)	10/16/1998 11:35:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

Merck Reaffirms 1998 Earnings Estimates at $4.27 to $4.34-Share Bloomberg News October 16, 1998, 10:56 a.m. ET Merck Reaffirms 1998 Earnings Estimates at $4.27 to $4.34-Share Whitehouse Station, New Jersey, Oct. 16 (Bloomberg) -- Merck & Co., the world's largest drugmaker, told analysts it's comfortable with estimates that put its 1998 profit at $4.27 to $4.34 a share, reaffirming the range it indicated in July. Merck fell 15/16 to 132 5/16 in midmorning trading amid concerns that its sales are not growing as quickly as they seem to be, analysts said. The Whitehouse Station, New Jersey-based company confirmed that it gave analysts the estimate range. Merck today said third-quarter net income rose to $1.37 billion, or $1.12 a share, from $1.20 billion, or 97 cents, in the year-earlier period. The results beat the $1.11-a-share average estimate of analysts polled by First Call Corp. Sales rose 15 percent to $6.84 billion from $5.93 billion. The recent quarter may include some items that Merck will not have in the future, analysts said. --Kerry Dooley in the Princeton newsroom (609) 279-4016/esk